What stage does CentreStone Ventures invest at?

CentreStone Ventures invests at the Pre-Seed, Seed, Series A stages.

What is CentreStone Ventures's typical check size?

CentreStone Ventures typically writes checks of $182.5K – $1.8M.

What sectors does CentreStone Ventures focus on?

CentreStone Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is CentreStone Ventures located?

CentreStone Ventures is headquartered in Winnipeg, CA.

CentreStone Ventures

Venture capital

Winnipeg · Pre-Seed–Series A · 3 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into CentreStone Ventures

1 people in our graph share verified history with the CentreStone Ventures team — schools, employers, funds. One of them is your warm intro.

Rick Paulsunlockedknows Albert D. Friesen · together at CentreStone Ventures

✨ Fox Verdict

Investment thesis

CentreStone Ventures backs early-stage life sciences companies developing therapeutics, medical devices, diagnostics and novel drug delivery methods. It targets companies addressing large markets with unmet clinical needs, built on strong intellectual property and a mix of entrepreneurial and technical talent with the potential to lead their markets. Based in Winnipeg at the geographic centre of North America, the firm sources opportunities from research centres across the continent, with particular focus on Western Canada and the U.S. Midwest. Beyond capital, CentreStone partners with scientific entrepreneurs, offering structure, support and guidance to build a foundation for commercial development.

Invests inBiotech Digital Health Healthtech Medical Devices Canada North America United States

Source: firm website, verified Aug 3, 2026.

Stage

Pre-Seed–Series A

Check

$182.5K – $1.8M

Winnipeg, Manitoba, CA

Instruments

Equity

Founded

2004

AUM

$18.3M

Tracked investments

IPOs

Team · 3 people

from the firm's website & public directories

Albert D. Friesen· Dr.

Holds a Ph.D. in Protein Chemistry from the University of Manitoba and was the first employee and President of the Winnipeg Rh Institute, overseeing the development of WinRho. He has founded several health industry companies including Novopharm Biotech (now Viventia Biotech), Genesys Pharma, Miraculins, Diamedica and Medicure, and has managed development of numerous pharmaceutical candidates.

a•••@centrestoneventures.comreveal

James Kinley· CA

A Chartered Accountant responsible for the financial operations and reporting of GVI and its client companies. He previously managed financial reporting at Manitoba Telecom Services and was an Audit Senior at Ernst & Young.

Marcus Enns· Vice President, Corporate Affairs

Holds a Bachelor of Commerce (Hons.) from the University of Manitoba and joined Genesys Venture Inc. in 2000. He oversees treasury and contract administration, supports fundraising for client companies, and has held executive roles at Miraculins and Kane Biotech.

What they invest in

from 1 of 1 portfolio companies

Biotech ×1Digital Health ×1

HQs:United States×1

Investments · 1 tracked

founders shown can be your intro path

DiaMedica Therapeuticsdiamedica.com in 𝕏NASDAQ: DMAC

DiaMedica Therapeutics develops therapies aimed at reducing ischemia in patients with serious vascular diseases, with an initial focus on preeclampsia, fetal growth restriction, and acute ischemic stroke.

BiotechDigital HealthMinneapolis, US

David J. Wambeke(Executive Officer)in Lorianne Masuoka(Executive Officer)inRick Pauls(Executive Officer, Director)inScott Kellen(Executive Officer)in Todd Verdoorn(Executive Officer)in Julie Krop(Chief Medical Officer)in

Co-investorsShepherd Ventures

Exits · 1

1 IPOs

DiaMedica TherapeuticsNASDAQ: DMAC

Portfolio news

latest coverage across their companies

DiaMedica Therapeutics (DMAC): BioTech with Breakthrough Potential

DiaMedica Therapeutics · finance.yahoo.com · Aug 3, 2026

IPO stake values · per SEC filings

Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.

Company	Owned	IPO price	At IPO	Stake value
DiaMedica Therapeutics	6.0%	$4.00	Dec 2018	$2.8M

Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).

Frequently asked questions

What stage does CentreStone Ventures invest at?: CentreStone Ventures invests at the Pre-Seed, Seed, Series A stages.
What is CentreStone Ventures's typical check size?: CentreStone Ventures typically writes checks of $182.5K – $1.8M.
What sectors does CentreStone Ventures focus on?: CentreStone Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is CentreStone Ventures located?: CentreStone Ventures is headquartered in Winnipeg, CA.

Similar investors

Amadeus Capital Partners

Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.

$50K – $12.7M

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Breyer Capital

Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.

$500K – $10M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

CABHI Ventures

CABHI (Centre for Aging + Brain Health Innovation) is a pan-Canadian organization that funds and supports researchers, innovators, and startups working on brain health and aging solutions, and helps healthcare and community organizations adopt them.